CD34+ Selected ASCT for Aggressive Lymphomas
NCT02646098
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
64
Enrollment
OTHER
Sponsor class
Conditions
Malignant Non-Hodgkin Lymphomas
Interventions
PROCEDURE:
CD34+ cell selection
Sponsor
Insel Gruppe AG, University Hospital Bern